Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3637 - First line therapy with aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas: a phase I-II study


10 Oct 2016


Poster display


Sant Chawla


Annals of Oncology (2016) 27 (6): 483-492. 10.1093/annonc/mdw388


S.P. Chawla1, K. Sankhala1, S. Chawla2, V. Chua1, E.M. Gordon1, N. Chawla1, K. Sung3, D. Quon1, K. Kim1, L. Fernandez1, B. Leong1, S. Wieland3, D. Levitt4

Author affiliations

  • 1 Med. Oncology, Sarcoma Oncology Center, 90403 - Santa Monica/US
  • 2 Clinical Development, CytRx Corporation, Los Angeles/US
  • 3 Clinical Operations, CytRx Corporation, Los Angeles/US
  • 4 Clinical, CytRx Corporation, 90049 - Los Angeles/US


Abstract 3637


Aldoxorubicin (A) has demonstrated superior anti-tumor efficacy and lack of cumulative cardiac toxicity in multiple studies. A is doxorubicin (D) with a linker which rapidly binds in vivo to albumin after iv administration. We studied the combination of A administered on Day 1 with continuous infusion (CI) of ifosfamide/Mesna (I-M) days 1-14, in patients with sarcomas to evaluate efficacy and toxicity.


27 patients entered the study at one of 2 dose levels of A:170 or 250 mg/m2 (125 or 185 mg/m2 D equiv) administered on Day 1. I-M (1 g/m2 of each per day) was given up to 14 days as a CI via an out-patient portable pump. Chemotherapy cycles were repeated at 28 day interval. I-M was limited to a maximum of 6 cycles to avoid cumulative marrow toxicity, but A was continued in responding patients for clinical benefit. Subjects were followed for tumor response by CT scans and echocardiogram for cardiac toxicity every 8 weeks along with standard labs.


Of the 27 patients enrolled as of May 1, 2016, the results of 24 evaluable patients are presented here. Twenty of the 24 patients had soft tissue sarcoma, 2 had metastatic osteosarcoma and 2 had dedifferentiated chondrosarcoma. Eight of 24 patients (33%) had a partial response (PR), 15/24 (62%) had stable disease (SD) and only 1/24 (5%) had progressive disease with over all disease control rate of 95% (PR + SD). Eleven of 24 (46%) patients had received at least 6 cycles of A (cumulative D equivalent more than 1000 mg/m2). Four patients were considered surgically resectable after 6 cycles of chemotherapy with percent of tumor necrosis of 95% and 90% in one patient each and 80% in two patients. Median duration of PFS was 6+ (2-19+) months. The most prevalent toxicity was gr 3 or 4 neutropenia. Four patients had SAEs of febrile neutropenia. There was no clinical cardiac toxicity/ congestive heart failure. No patient had LVEF 


The combination of A + I-M appears to be superior in anti-tumor efficacy to D/I-M with durable responses. A + I-M combination is quite tolerable with expected reversible hematologic toxicity. Of the 46% patients who received more than 1000 mg /m2 of D equivalent; no cardiac toxicity was observed.

Clinical trial identification


Legal entity responsible for the study

CytRx Corporation


CytRx Corporation


S.P. Chawla: Research support from CytRx Corporation. S. Chawla, K. Sung, S. Wieland, D. Levitt: Employee of CytRx Corporation. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings